Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
Cancer Medicine · 2023
DOI: 10.1002/cam4.6310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Kusha A Mohammadi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Neoplasms, PCSK9 Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regeneron Pharmaceuticals.
Abstract (Originalsprache)
Objective
Assess the risk of new and worsening cancer events among participants who received the lipid‐lowering therapy alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor.
Design
Pooled post hoc analysis.
Setting
Six phase 3 or phase 4 placebo‐controlled randomised trials with alirocumab.
Participants
A total of 24,070 patients from the safety population with complete dosing data (alirocumab, n = 12,533; placebo, n = 11,537).
Intervention
Alirocumab 75 mg, alirocumab 150 mg, alirocumab 75 mg increasing to 150 mg if low‐density lipoprotein cholesterol
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
- University of Colorado School of Medicine, Aurora, Colorado, USA.
- Université Paris-Cité, Paris, France.
- FACT (French Alliance for Cardiovascular Trials) INSERM U1148, Paris, France.
- Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
- State University of New York, Downstate School of Public Health, Brooklyn, New York, USA.
ORCID-Profile: Gregory P Geba
Förderung
- Regeneron Pharmaceuticals
Zitieren
APA
Mohammadi, K. A., Brackin, T., Schwartz, G. G., Steg, P. G., Szarek, M., Manvelian, G., Pordy, R., Fazio, S., & Geba, G. P. (2023). Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Medicine. https://doi.org/10.1002/cam4.6310
Vancouver
Mohammadi KA, Brackin T, Schwartz GG, Steg PG, Szarek M, Manvelian G, et al. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Medicine. 2023. doi:10.1002/cam4.6310
BibTeX
@article{Mohammadi2023,
author = {Mohammadi, Kusha A and Brackin, Taylor and Schwartz, Gregory G and Steg, Philippe Gabriel and Szarek, Michael and Manvelian, Garen and Pordy, Robert and Fazio, Sergio and Geba, Gregory P},
title = {Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6310}
}
EUVIMED